Clinical Trial: Risks of Ramadan Fasting in Patients With Primary Adrenal Insufficiency Treated With Prednisolone.

U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07367425) titled 'Risks of Ramadan Fasting in Patients With Primary Adrenal Insufficiency Treated With Prednisolone.' on Jan. 16.

Brief Summary: In primary adrenal insufficiency (PAI), there is a risk of hypoglycemia and dehydration. These risks seem to be increased during intermittent fasting. A previous study in patients with PAI treated with hydrocortisone at a dose of 20 mg/day showed that the prevalence of hypoglycemia was as high outside (63%) as during Ramadan fasting (71%), and that there was no risk of dehydration. We propose to evaluate the risk of complications during and outside of Ramadan fasting through a prospective study with subjects...